Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study to Determine the Safety and Biological Activity of Cell-Mediated Gene Therapy Using TissueGene-C in Patients With Degenerative Joint Disease Prior to Total Knee Arthroplasty

Trial Profile

A Phase 1 Study to Determine the Safety and Biological Activity of Cell-Mediated Gene Therapy Using TissueGene-C in Patients With Degenerative Joint Disease Prior to Total Knee Arthroplasty

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tonogenchoncel-L (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions; First in man
  • Sponsors Kolon TissueGene; TissueGene
  • Most Recent Events

    • 16 Mar 2018 According to a Kolon TissueGene media release, TissueGene changed its name to Kolon TissueGene.
    • 29 Jun 2016 Time frame of primary end point changed from Days 0, 3, 7, 11, 28, 29 and at 3, 6, 9, and 12 months following dosing to through 28 days post-dosing.
    • 18 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top